Amylin’s Obesity Pipeline Advances
Zacks.com submits:
Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies.
The decision is based on encouraging 52-week results on the combination treatment from a blinded, placebo-controlled phase II extension study in which the combination succeeded in achieving the key target of sustained and robust weight loss.
Investing, Long Term Investment, stock market | admin February 25, 2010
RSS feed for comments on this post.
